MPO and APOEε4 polymorphisms interact to increase risk for AD in Finnish males

Background: Myeloperoxidase (MPO) is present in senile plaques and surrounding reactive microglia, but not in normal brain parenchyma. MPO in plaques is highest in APOE ε4 carriers, suggesting a functional interaction. An MPO promoter polymorphism (-463G/A) linked to increased MPO expression has been associated with increased risk of AD. Methods: To further define the possible interaction of MPO and APOE ε4, we examined 127 patients with AD and 174 controls from a genetically homogeneous Finnish population. Results: A significantly higher percentage of male patients with AD carried the MPO A and APOE ε4 alleles relative to men carrying neither allele (p < 0.001; OR, 11.4; 95% CI, 3.6 to 6.7). Male APOE ε4 carriers lacking the MPO A allele had an OR of 3.0 (p = 0.01; 95% CI, 1.3 to 6.9), indicating that MPO A enhances AD risk by 3.8-fold. Age at onset was lower in men carrying the MPO A and APOE ε4 alleles (Kaplan—Meier survival analysis; p = 0.01). Also, the MPO AA genotype was associated with selective mortality in men, but not in women. AA genotypes were absent from 159 male patients with AD and controls, representing the expected 5% to 6% in women and male controls younger than age 20. The -463A creates an estrogen receptor binding site that may contribute to these gender differences. Conclustions: MPO A and APOE ε4 alleles interact to increase the risk of AD in men but not in women in this Finnish cohort.